EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieRandomisierte kontrollierte StudieÄquivalenzstudieOpen Access

VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19

Zhujun Cao iD, Weiyi Gao, Hong Bao, Haiyan Feng, Shuya Mei, Peizhan Chen, Yueqiu Gao, Zhilei Cui, Qin Zhang, Xianmin Meng, Honglian Gui, Weijing Wang und 10 weitere

New England Journal of Medicine · 02.02.2023 · 388 (5) · 406-417

DOI: 10.1056/nejmoa2208822 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 02.02.2023. Verfasst von Zhujun Cao und 21 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Infectious Diseases, Shanghai Institute of Virology (Z. Cao, H.G., W.W., Q.X.), the Department of Emergency Medicine, Shanghai…. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19, COVID-19 Drug Treatment. Die Arbeit wurde bisher 196-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Science and Technology Commission of Shanghai Municipality, National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCOVID-19COVID-19 Drug TreatmentAdultHumansRitonavirSARS-CoV-2Administration, OralSingle-Blind MethodDisease ProgressionAdenosineLactamsLeucineNitrilesProlineDrug Combinations

Substanzen

Antiviral AgentsRitonavirGS-621763AdenosinenirmatrelvirLactamsLeucineNitrilesProlinenirmatrelvir and ritonavir drug combination

Autor:innen und Institutionen

  • From the Department of Infectious Diseases, Shanghai Institute of Virology (Z. Cao, H.G., W.W., Q.X.), the Department of Emergency Medicine, Shanghai Innovation Center for Digital Medicine (W.G.), the Clinical Research…

ORCID-Profile: Zhujun Cao

Förderung

  • Science and Technology Commission of Shanghai Municipality
  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Shanghai Municipal Key Clinical Specialty
  • Lingang Laboratory emergency project
  • Vigonvita Life Science Co., Ltd
  • Shanghai Shenkang Three-Year Action grant

Zitieren

APA

Cao, Z., Gao, W., Bao, H., Feng, H., Mei, S., Chen, P., Gao, Y., Cui, Z., Zhang, Q., Meng, X., Gui, H., Wang, W., Jiang, Y., Song, Z., Shi, Y., Sun, J., Zhang, Y., Xie, Q., Xu, Y., …, & Zhao, R. (2023). VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19. New England Journal of Medicine, 388(5), 406-417. https://doi.org/10.1056/nejmoa2208822

Vancouver

Cao Z, Gao W, Bao H, Feng H, Mei S, Chen P, et al. VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19. New England Journal of Medicine. 2023;388(5):406-417. doi:10.1056/nejmoa2208822

BibTeX
@article{Cao2023,
  author = {Cao, Zhujun and Gao, Weiyi and Bao, Hong and Feng, Haiyan and Mei, Shuya and Chen, Peizhan and Gao, Yueqiu and Cui, Zhilei and Zhang, Qin and Meng, Xianmin and Gui, Honglian and Wang, Weijing and Jiang, Yimei and Song, Zijia and Shi, Yiqing and Sun, Jing and Zhang, Yifei and Xie, Qing and Xu, Yiping and Ning, Guang and Gao, Yuan and Zhao, Ren},
  title = {VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {388},
  number = {5},
  pages = {406--417},
  doi = {10.1056/nejmoa2208822}
}
Kostenlos starten →